文献速递临床试验与 GCP

高流量鼻导管氧疗的急性低氧性呼吸衰竭患者俯卧位与侧卧位比较:多中心随机对照开放标签试验的研究方案

Prone versus lateral position in acute hypoxemic respiratory failure patients with HFNO therapy: study protocol for a multicentre randomised controlled open-label trial.
PubMed 文献 · Trials · 2023-11-27

本研究为三臂平行组多中心随机对照开放标签探索性试验方案,拟纳入中国重庆两家医院583例非COVID-19肺炎或肺部感染所致急性低氧性呼吸衰竭并接受高流量鼻导管氧疗的患者,按1:1:1随机分为半卧位、侧卧位或俯卧位组。主要结局为28天内无呼吸机天数,次要结局包括28天插管率、28天全因死亡率、总体位改变时间、不良事件发生率、高流量鼻导管氧疗使用小时数及住院和ICU停留时间等。

要点

  • 方案拟纳入583例接受高流量鼻导管氧疗的非COVID-19急性低氧性呼吸衰竭患者,随机分为半卧位、侧卧位、俯卧位三组。
  • 主要结局为28天内无呼吸机天数,次要结局包括28天插管率、28天全因死亡率及不良事件发生率等。
  • 将按PaO2/FiO2比值(>200 mmHg或≤200 mmHg)、入院至干预时间(<24 h或≥24 h)等进行亚组分析。

核心结论

  • 该试验将探讨清醒俯卧位与侧卧位对非COVID-19急性低氧性呼吸衰竭清醒患者的预后影响并比较两者差异,为体位管理的临床决策和进一步研究提供证据。

研究设计与样本

  • 三臂平行组多中心随机对照开放标签探索性试验方案,拟纳入中国重庆两家医院共583例患者。
  • 患者按1:1:1随机接受半卧位、侧卧位或俯卧位,均为非COVID-19肺炎或肺部感染所致急性低氧性呼吸衰竭并接受高流量鼻导管氧疗。
  • 主要结局为28天内无呼吸机天数;次要结局包括28天插管率、28天全因死亡率、总体位改变时间、不良事件发生率、高流量鼻导管氧疗使用小时数、住院和ICU停留时间等。
  • 亚组分析按PaO2/FiO2比值(>200 mmHg或≤200 mmHg)、入院至干预实施时间(<24 h或≥24 h)、体位改变时间和不同诊断进行。
  • 该试验已在中国临床试验注册中心注册,注册号为ChiCTR2200055822,注册日期为2022年1月20日。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-flow nasal oxygen (HFNO) therapy is a leading treatment technique for acute hypoxemic respiratory failure (AHRF), but its treatment failure rate remains high. The awake prone position (APP) has been proven to increase oxygenation and reduce the endotracheal intubation rate in patients with COVID-19-induced AHRF. However, the APP is poorly tolerated in patients, and its performance in improving prognoses is controversial. The lateral position has a similar mechanism and effect to the prone position, but it is more tolerable than the prone position. Therefore, it is worth exploring whether the lateral position is better for awake patients with AHRF. METHODS: This is a protocol for a three-arm parallel-group multicentre randomised controlled open-label exploratory trial. A total of 583 patients from two hospitals in Chongqing, China, will be randomised to take the semi-recumbent position, lateral position, or prone position at a ratio of 1:1:1. Patients are all diagnosed with AHRF secondary to non-COVID-19 pneumonia or lung infection and receiving HFNO therapy. The primary outcome is ventilator-free days in 28 days. The secondary outcomes are the 28-day intubation rate, 28-day all-cause mortality, total position change time, the incidence of adverse events, number of hours using HFNO therapy, length of hospital and intensive care unit (ICU) stay, and others. We will conduct subgroup analyses on the arterial partial pressure of oxygen to the fraction of inspiration oxygen (PaO2/FiO2) ratio (> 200 mmHg or ≤ 200 mmHg), time from admission to intervention implementation (< 24 h or ≥ 24 h), position changing time, and different diagnoses. DISCUSSION: This trial will explore the prognostic effects of the APP with that of the lateral position in awake patients with non-COVID-19AHRF and compare the differences between them. To provide evidence for clinical decision-making and further research on position management. TRIAL REGISTRATION: This trial was registered in the Chinese Clinical Trial Registry. The registration number is ChiCTR2200055822 . Registered on January 20, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhou X, Luo X, Li Q, et al. Prone versus lateral position in acute hypoxemic respiratory failure patients with HFNO therapy: study protocol for a multicentre randomised controlled open-label trial. Trials. 2023. PMID: 38012708. doi:10.1186/s13063-023-07761-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。